The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Gut

Volumn 63, Issue 8, 2014, Pages 1258-1264

  Ungar, Bella ^a   Chowers, Yehuda ^b   Yavzori, Miri ^a   Picard, Orit ^a   Fudim, Ella ^a   Har Noy, Ofir ^a   Kopylov, Uri ^a   Eliakim, Rami ^a   Ben Horin, Shomron ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY TO INFLIXIMAB; DRUG ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; ONSET AGE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

IBD CLINICAL; IMMUNOLOGY; INFLIXIMAB;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84904063633     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305259     Document Type: Article

References (31)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long- Term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
5. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. (Pubitemid 38834038)
6. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
7. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F (ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011;60:41-8.
8. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor- Alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8. (Pubitemid 351501078)
9. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta- Analysis. Am J Gastroenterol 2013;108:40-7; quiz 48.
10. Ordas I, Mould DR, Feagan BG, et al. Anti- TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-46.
11. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349-58.
12. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti- TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-66.
13. Van de Casteele N, Gils A, Singh S, et al. Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient. Am J Gastroenterol 2013;108:962-71.
14. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
15. Higgins PD, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782-8. (Pubitemid 40732094)
16. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
17. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;8:357-63.
18. Ben-Horin S, Chowers Y. Review article: loss of response to anti- TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011;33:987-95.
19. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012;18:1628-33.
20. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54. (Pubitemid 44512213)
21. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70; quiz e31.
22. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 2008;134:1861-8. (Pubitemid 351790744)
23. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review. Am J Gastroenterol 2009;104:760-7.
24. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
25. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-7.
26. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31. (Pubitemid 47300423)
27. Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010;59:7-8.
28. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87; quiz e85-6.
29. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti- Tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591.
30. Casteele NV, Compernolle G, Ballet V, et al. Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohn Colitis 2012;6(Suppl 1):S6.
31. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2209-17.